Guilherme Monteiro Ferreira

Guilherme Monteiro Ferreira

Auto-generated profile, based on publicly available information

Guilherme Monteiro Ferreira

Universidade Presbiteriana Mackenzie, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PJPaulo Jaworski
Paulo Jaworski
GMGregório Fadel Mello
Gregório Fadel Mello
GFGuilherme Monteiro Ferreira
Guilherme Monteiro Ferreira
MOMaria Helena Oliveira
Maria Helena Oliveira
RFRogerio de Fraga
Rogerio de Fraga
Ureteral stents usually cause pain and lower urinary tract discomfort. This study aimed to compare the effect of mirabegron with oxybutynin in relieving ureteral stent-related symptoms over time. A prospective, longitudinal, randomized, single-blinded study was conducted. Patients who had a ureteral stent inserted after urolithiasis treatment were classified into two groups and received either oxybutynin 5 mg/day (Group O) or mirabegron 50 mg/day (Group M). The Ureteral Stent Symptoms Questionnaire (USSQ) was applied on the 3rd, 6th, and 15th postoperative days. Group domain scores were compared, and a mixed linear model was used to better assess score differences. Ureteral Stent Symptoms Questionnaire scores were similar in both groups during all three postoperative days (p>0.05). A longitudinal analysis showed that global quality of life and general health improved over time, independently of the use of any of the medications (p<0.05), while urinary symptoms and body pain scores were lower over time in participants receiving oxybutynin. Both mirabegron and oxybutynin are equivalent in relieving ureteral stent symptoms. Moreover, some stent symptoms seem to decrease over time despite the use of medication.